Skip to main content
Premium Trial:

Request an Annual Quote

Geneoscopy Raises $6.9M in Series A Financing

NEW YORK – Geneoscopy announced today that it has raised $6.9 million in a Series A financing round. 

The St. Louis-based startup will use the funding to develop its colorectal cancer (CRC) screening assay, which measures eukaryotic RNA isolated from epithelial cells in stool to diagnose CRC and advanced adenomas. 

The financing round was led by Cultivation Capital and NT Investments. Lightchain Capital was also a significant investor in the round. 

Following the financing round, Cultivation General Partner Bobby Sandage, Lightchain Managing Director Drew Dennison, and NT Investments' Najeeb Thomas are joining Geneoscopy's board of directors. 

"Geneoscopy's research has shown that stool-derived eukaryotic RNA biomarkers are highly sensitive for both the presence of cancer and, more importantly, precancerous lesions," Sandage said in statement. "High sensitivity for precancerous lesions, or adenomas, is particularly important for CRC prevention."

"We are excited to work with our new partners to continue the development of our CRC screening test and other applications of our platform technology," Geneoscopy CEO Andrew Barnell said in a statement. "We appreciate their support of our mission to prevent avoidable health conditions from impacting the lives of patients."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.